Eisai, Biogen move Alzheimer’s treatment into Phase III by Anna Smith | Mar 26, 2019 | News | 0 Eisai and Biogen’s BAN2401 is to be put into Phase III trial for patients with early Alzheimer’s disease. Read More
Eisai, Biogen’s Alzheimer’s candidate shows promise in PhII trial by Selina McKee | Jul 6, 2018 | News | 0 At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease. Read More